Infectious Diseases

Regulatory approval granted in Columbia for Impavido for leishmaniasis

Published in Drug Week, April 29th, 2005

AEterna Zentaris, Inc., (AEZ; AEZS) announced that it has received Colombian Food and Drug Agency approval for Impavido (miltefosine) to treat the cutaneous form of leishmaniasis, a severe parasitic skin disease estimated to affect millions of people worldwide.

This is the first-ever approval of Impavido for this form of leishmaniasis. The approval also applies for the visceral form (black fever) of leishmaniasis for which Impavido had already received approval by the Indian and German Regulatory Authorities. Impavido thus becomes the first orally administered, breakthrough therapy for both visceral and cutaneous leishmaniasis.

Impavido, or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-04-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry